Kihara James 4

What Happened
James Kihara, Principal Accounting Officer of ACADIA Pharmaceuticals (ACAD), converted restricted stock units (RSUs) into common shares and sold a total of 1,942 shares in open-market transactions to cover tax withholding. The sales occurred on March 25–26, 2026 for total proceeds of approximately $41,896. The filing also records the RSU conversions (derivative exercises) on March 24–25, 2026.

Key Details

• Insider: James Kihara, Principal Accounting Officer. Filing date: 2026-03-26 (reporting period includes transactions beginning 2026-03-24). Filing appears timely.
• Sales (open market/private sale):
  • 2026-03-25: 833 shares @ $21.47 = $17,885
  • 2026-03-26: 1,097 shares @ $21.65 = $23,750
  • 2026-03-26: 12 shares @ $21.73 = $261
  • Total sold: 1,942 shares for ~$41,896
• Derivative/vesting activity:
  • 2026-03-24: 1,627 RSUs converted to shares (reported as acquired)
  • 2026-03-25: 2,142 RSUs converted to shares (reported as acquired)
  • Additional derivative entries show conversions recorded at $0.00, indicating non-cash conversion of units to shares.
• Footnotes:
  • F1: Each RSU represents a contingent right to one share.
  • F2: Sales were mandatory to cover withholding taxes and intended to comply with Rule 10b5-1(c) requirements.
  • F3/F4: Two RSU grants appear to have different vesting schedules (four equal annual installments beginning 3/24/2026 and 3/25/2025).
• Shares owned after the transactions are not specified in the provided filing excerpt.

Context
These transactions look like routine, tax-withholding sales tied to RSU vesting rather than discretionary insider selling for investment reasons. In plain terms: RSUs vested (converted into shares), and some of those shares were immediately sold to satisfy tax obligations — a common "sell-to-cover" practice. Such transactions generally carry less information about the insider's view of the company compared with voluntary, substantial open-market purchases.